Clinical trials: Thrombotic Microangiopathies
Thrombocytopenia, Idiopathic Thrombocytopenic Purpura
AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy
The purpose of this study is to evaluate the efficacy of AMG 531 in the treatment of thrombocytopenia in subjects with ITP as measured by the platelet response.
- Trial name
- NCT00102323
- Testing
- AMG 531
- Volunteers
- 63 people
- Sponsor
- Amgen
Immune Thrombocytopenia, Treatment
A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia
To evaluate the safety and efficacy of nicotinamide adenine dinucleotide in the treatment of immune thrombocytopenia in patients who have not responded adequately or relapsed after first-line treatment and at least one…
- Trial name
- NCT06776510
- Testing
- nicotinamide adenine dinucleotid/nicotinamide mononucleotide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Idiopathic Thrombocytopenic Purpura
Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITP
It is a phase III multicenter randomized double-blinded comparative study of clinical efficacy and safety of GNR-069 and Nplate in patients with idiopathic thrombocytopenic purpura
- Trial name
- NCT05220878
- Testing
- GNR-069, Nplate
- Where
- 18 sites in Russia
- Volunteers
- 160 people
- Sponsor
- AO GENERIUM
Immune Thrombocytopenia
Efficacy and Safety Assessment of a Treatment Combining Rituximab and Belimumab in Adults With Persistent Immune Thrombocytopenia
Previous studies have shown that increase level of BAFF could promote the settlement of long-lived plasma cells in the spleen of ITP patients treated with anti-CD20.
- Trial name
- RITUX PLUS (NCT03154385)
- Testing
- Rituximab (Mabthera ®) Belimumab (Benlysta ®)
- Where
- France
- Volunteers
- 15 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Idiopathic Thrombocytopenic Purpura (ITP), Immune Thrombocytopenic Purpura (ITP)
Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP)
The purpose of the study is to evaluate the safety and efficacy of rituximab in children ages 18 months to 18 years, who have severe, chronic ITP.
- Trial name
- NCT01713738
- Testing
- rituximab
- Where
- 9 sites in United States
- Volunteers
- 36 people
- Sponsor
- Neufeld, Ellis J, MD, PhD
Purpura, Thrombocytopaenic, Idiopathic
Repeated Exposure to Eltrombopag in Adults With Idiopathic Thrombocytopenic Purpura (REPEAT)
This open-label, repeat dosing study, TRA108057, will evaluate the efficacy, safety and tolerability of eltrombopag, when administered in a repeat, cyclic dosing schedule.
- Trial name
- NCT00424177
- Testing
- eltrombopag
- Where
- 3 sites in Germany, Russia
- Volunteers
- 66 people
- Sponsor
- GlaxoSmithKline
Thrombotic Thrombocytopenic Purpura (TTP)
A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)
Thrombotic thrombocytopenic purpura (or TTP for short) is a condition where blood clots form in small blood vessels throughout the body.
- Trial name
- NCT03393975
- Testing
- TAK-755, Standard of care
- Where
- 33 sites in United States, Austria and 7 more
- Volunteers
- 52 people
- Sponsor
- Baxalta now part of Shire
Immune Thrombocytopenic Purpura
Efficacy of Rapamycin Therapy With Chronic Immune Thrombocytopenia
The aim of our study is to evaluate the efficacy of rapamycin with Refractory Immune Thrombocytopenic Purpura (RITP) and explore the further mechanism.
- Trial name
- ITP (NCT01672151)
- Testing
- rapamycin
- Where
- China
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Suzhou Medical College
Immune Thrombocytopenia
Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months
A Phase 3b Study to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects with Immune Thrombocytopenia for ≥6 Months
- Trial name
- NCT04516967
- Testing
- Avatrombopag
- Where
- 62 sites in United States, France and 7 more
- Volunteers
- 75 people
- Sponsor
- Sobi, Inc.
Chronic Idiopathic Thrombocytopenic Purpura, Purpura, Thrombocytopenic, Idiopathic
Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP)
This is a Phase II/III multicenter study comprising of the double-blind, followed by open-label phases to evaluate and compare the efficacy and tolerability of eltrombopag (SB-497115-GR) in chronic ITP patients
- Trial name
- NCT00540423
- Testing
- SB-497115-GR 12.5mg, SB-497115-GR 25mg, SB-497115-GR 50 mg
- Where
- 7 sites in Japan
- Volunteers
- 23 people
- Sponsor
- GlaxoSmithKline
Immune Thrombocytopenia
Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
This is a multinational, open label, single arm study that will evaluate the impact of early multi-immune modulation with rilzabrutinib in adult ITP patients who failed first-line treatment.
- Trial name
- LUNA 4 (NCT07007962)
- Testing
- rilzabrutinib
- Where
- 36 sites in United States, Austria and 7 more
- Volunteers
- 60 people
- Sponsor
- Sanofi
ITP - Immune Thrombocytopenia, Primary Immune Thrombocytopenia (ITP)
RESTI Registry: Spanish Registry of Primary Immune Thrombocytopenia and Other Immune Thrombocytopenia
Primary immune thrombocytopenia (PIT), previously referred to as idiopathic thrombocytopenic purpura, is an acquired disease characterized by accelerated platelet destruction and deficient platelet production by megakaryocytes.
- Trial name
- RESTI (NCT06919341)
- Where
- 36 sites in Spain
- Volunteers
- 1,000 people
- Sponsor
- Fundación Española de Hematología y Hemoterapía
Immune Thrombocytopenia, Blood Coagulation Disorders
The Combination of Sitagliptin and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
Randomized, open-label, multicenter study to compare the efficacy and safety of combination of Sitagliptin and danazol versus danazol for the treatment of adults with steroid-resistant/relapse immune thrombocytopenia (ITP).
- Conditions
- Immune Thrombocytopenia, Blood Coagulation Disorders, Thrombocytopenia, Physiological Effects of Drugs
- Trial name
- NCT05353673
- Testing
- Sitagliptin, Danazol
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Peking University People's Hospital
AIHA - Warm Autoimmune Hemolytic Anemia, AIHA - Cold Autoimmune Hemolytic Anemia
OM336 in Autoimmune Cytopenias
An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cytopenias.
- Conditions
- AIHA - Warm Autoimmune Hemolytic Anemia, AIHA - Cold Autoimmune Hemolytic Anemia, ITP - Immune Thrombocytopenia
- Trial name
- NCT07083960
- Testing
- OM336
- Where
- 7 sites in United States, Australia
- Volunteers
- 32 people
- Sponsor
- Lakefront Biotherapeutics West LLC
Purpura, Thrombocytopenic, Idiopathic
Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP
The objective of this study is to determine if the safety and tolerability of Immune Globulin Intravenous (Human), 10% Caprylate/Chromatograph Purified (IGIV-C) is similar when infused at two different infusion rates.
- Trial name
- NCT00220727
- Testing
- Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Grifols Therapeutics LLC
Thrombotic Thrombocytopenic Purpura
ADAMTS13 in Thrombotic Thrombocytopenic Purpura
Thrombotic thrombocytopenic purpura (TTP) is a thrombotic microangiopathy defined by the spontaneous formation of platelet thrombi in the microvessels.
- Trial name
- ADAMTS13 (NCT00426686)
- Where
- France
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Immune Thrombocytopenia
PRTX-100-202 Open-Label, Dose Escalation Study in Adult Patients With ITP
Pre-clinical and clinical evaluations show that PRTX- 100 has biological activity that may lead to improved platelet levels where these are decreased due to immunological pathologies and that PRTX-100 has an acceptable safety…
- Trial name
- NCT02401061
- Testing
- PRTX-100
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 13 people
- Sponsor
- Protalex, Inc.
Immune Thrombocytopenia Purpura
Immune Thrombocytopenia Management in Adults
Immune thrombocytopenia treatment has evolved recently. However, none of treatments have only benefits without drawbacks. This study compares the clinical outcomes and adverse drug patterns of different treatment options.
- Trial name
- NCT05861297
- Testing
- Dexamethasone, Prednisolone and Azathioprine, Rituximab
- Where
- Egypt
- Volunteers
- 467 people
- Sponsor
- Nahda University
Immune Thrombocytopenia (ITP)
National Multicenter Retrospective Real-World Study on the Treatment Status of Newly Diagnosed and Persistent Primary Immune Thrombocytopenia (ITP) Patients
This study is a nationwide, multicenter, retrospective, real-world, non-interventional (observational) investigation. It retrospectively collects data on treatment modalities and therapeutic responses in patients with newly…
- Trial name
- NCT07268898
- Volunteers
- 500 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Immune Thrombocytopenia
The Combination of ATRA and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia
Randomized, open-label, multicenter study to compare the efficacy and safety of ATRA plus high-dose dexamethasone compared to high-dose dexamethasone monotherapy for the first-line treatment of adults with primary immune…
- Trial name
- NCT04217148
- Testing
- Dexamethasone, ATRA
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Peking University People's Hospital